-
公开(公告)号:WO2023078378A1
公开(公告)日:2023-05-11
申请号:PCT/CN2022/129773
申请日:2022-11-04
Applicant: 华熙生物科技股份有限公司
IPC: A61K31/728 , A61K47/36 , A61P37/04 , A61P29/00 , A23L33/125 , A61P1/00
Abstract: 一种提高机体免疫力、保护胃肠道健康的含透明质酸或其盐的组合物及其应用。所述的含透明质酸或其盐的组合物,其包含三种分子量透明质酸或其盐。组合物通过协同增效实现增强免疫力、缓解肠道炎症、促进肠道蠕动、调节肠道菌群的作用,可作为功效成分添加于食品及保健类食品中,也可作为辅料,与药物联合使用。
-
2.
公开(公告)号:WO2023057499A1
公开(公告)日:2023-04-13
申请号:PCT/EP2022/077675
申请日:2022-10-05
Applicant: COSMO TECHNOLOGIES LTD
Inventor: GERLONI, Mara , MACELLONI, Cristina , ROSETTE, Caridad , LONGO, Luigi
IPC: A61K9/08 , A61P1/00 , A61K47/10 , A61K47/36 , A61K47/38 , A61K9/00 , A61K31/395 , A61K9/0031
Abstract: The present disclosure relates to an (in situ gelling) enema containing Rifamycin SV and its use in the treatment of pouchitis, proctitis and/or distal ulcerative colitis (including proctosigmoiditis). More particularly, the present disclosure describes an in situ gelling retentive enema containing Rifamycin SV for treating, ameliorating, reducing the severity of or slowing the progression of pouchitis, proctitis and/or distal ulcerative colitis (including proctosigmoiditis).
-
公开(公告)号:WO2023047413A1
公开(公告)日:2023-03-30
申请号:PCT/IN2022/050842
申请日:2022-09-21
Applicant: GODAVARI BIOREFINERIES LIMITED
Inventor: REDASANI, Vijayendra , GAVADE, Sandip , ATHAVALE, Maithili , KHARKAR, Prashant
IPC: A61K9/20 , A61K9/16 , A61K47/32 , A61K47/36 , A61K31/36 , A61K31/4025 , A61K31/7048 , A61P35/00
Abstract: The present invention relates to pharmaceutical compositions comprising compound of Formula IV, along with a solubilizing agent and a process to prepare the same. The said pharmaceutical compositions have enormous applications in cancer therapy. The present invention has come up with a novel and innovative pharmaceutical composition for the compounds of Formula IV that show significant stability as well as the desired bioavailability on drug release.
-
4.
公开(公告)号:WO2023044132A2
公开(公告)日:2023-03-23
申请号:PCT/US2022/044032
申请日:2022-09-19
Applicant: WALKER, Shawn
Inventor: WALKER, Shawn
IPC: A61K47/36 , A61P31/14 , A61K31/715 , A61K47/61
Abstract: The invention provides methods of blocking access to, and reducing infiltration into, the brain of a subject through the subject's olfactory nerves, olfactory support structures, or both, of one or more undesirable environmental factors by contacting the surface of the olfactory epithelium with a chitosan complex, a chitosan composition, or a mixture of the two.
-
公开(公告)号:WO2023042900A1
公开(公告)日:2023-03-23
申请号:PCT/JP2022/034694
申请日:2022-09-16
Applicant: 富士化学工業株式会社
IPC: A61K31/7024 , A61K9/06 , A61K47/26 , A61K47/36 , A61P1/04
Abstract: スクラルファート水和物を含有するゼリー状医薬組成物を提供する。 スクラルファート水和物を含有するゼリー状医薬組成物であって、カンテンをゼリー基剤とするゼリー状医薬組成物。
-
公开(公告)号:WO2023034881A1
公开(公告)日:2023-03-09
申请号:PCT/US2022/075789
申请日:2022-08-31
Applicant: ELIXIRGEN THERAPEUTICS, INC.
Inventor: KO, Minoru S. H.
IPC: A61K39/00 , C12N15/62 , C12N15/86 , A61K39/215 , A61P31/14 , C07K14/005 , C07K14/18 , C07K14/47 , C08B37/08 , A61K47/36 , A61K9/00 , A61P35/00
Abstract: The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding a cancer antigen. The RNA constructs are suitable for cancer immunotherapy in a mammalian subject, such as a human subject.
-
公开(公告)号:WO2023030430A1
公开(公告)日:2023-03-09
申请号:PCT/CN2022/116432
申请日:2022-09-01
Applicant: 成都瑞沐生物医药科技有限公司
IPC: A61K9/08 , A61K9/10 , A61K9/107 , A61K31/575 , A61K31/56 , A61K47/26 , A61K47/10 , A61K47/38 , A61K47/36 , A61K47/58 , A61P27/12 , A61P27/02
Abstract: 一种滴眼给药防治白内障的眼用制剂,由治疗眼病的活性物质和药学上可接受的载体或辅料组成;治疗眼病的活性物质为氧化型胆甾醇,包括羊毛甾醇或25-羟基胆甾醇;所述药学上可接受的载体或辅料含有:表面活性剂、增粘剂、助溶剂和溶剂;所述制剂中氧化型胆甾醇含量为0.01~5mg/mL;表面活性剂、增粘剂、助溶剂和氧化型胆甾醇的质量比为(1~300):(1~100):(100~3000):1,余量为溶剂。所述制剂在滴眼给药后,可以使活性物质选择性富集在实验动物的晶状体,精准发挥治疗白内障的作用,并且活性物质不分布在房水、玻璃体中,避免对其它眼组织和对全身的毒副作用。解决了眼科用药递送领域人们一直渴望解决的技术难题,具有极高的临床应用价值和社会价值。
-
公开(公告)号:WO2023025231A1
公开(公告)日:2023-03-02
申请号:PCT/CN2022/114705
申请日:2022-08-25
Applicant: 丽珠医药集团股份有限公司
IPC: A61K47/36 , A61K47/42 , A61K9/16 , A61K31/4439 , A61P1/00 , A61P29/00 , A61P1/04 , A61P37/08 , A61P1/14 , A61P31/04 , A61P7/04
Abstract: 本发明涉及用于干混悬剂的干混悬颗粒,包含所述干混悬颗粒的干混悬剂,及其制备方法和用途。该干混悬颗粒包含阴离子型凝胶剂和阳离子型聚合物,其中,所述阴离子型凝胶剂与所述阳离子型聚合物的重量比为(0.5~50):1。
-
公开(公告)号:WO2023018649A1
公开(公告)日:2023-02-16
申请号:PCT/US2022/039699
申请日:2022-08-08
Applicant: BAYER HEALTHCARE LLC
Inventor: BRADLEY, Reginald , DAS, Debanjan , MEISEL, Gerard
Abstract: The present disclosure relates generally to formulations for gastric and gastroesophageal disorders, such as gastroesophageal reflux disorder (GERD) acid reflux, peptic ulceration, acute and/or chronic gastritis, and other disorders, and more specifically to formulations comprising alginic acid or pharmaceutically acceptable salts thereof, pectin, and carrageenan. The liquid formulations described herein demonstrate long-lasting mucoadhesion and raft-forming ability. The present disclosure also provides methods of using the liquid formulations described herein for treatment of such gastric and gastroesophageal disorders.
-
公开(公告)号:WO2023017834A1
公开(公告)日:2023-02-16
申请号:PCT/JP2022/030526
申请日:2022-08-10
Applicant: 国立大学法人山形大学 , 伊勢化学工業株式会社
IPC: A01N25/00 , A01N25/02 , A01N25/18 , A01N59/12 , A01P1/00 , A01P3/00 , A61K9/08 , A61K9/14 , A61K9/70 , A61K33/18 , A61K47/02 , A61K47/10 , A61K47/36 , A61K47/69 , A61P17/00 , A61P31/04 , A61P31/10 , A61P31/12
Abstract: 本発明は、新規なヨウ素系消毒剤、そのような消毒剤を含む消毒フィルム及び消毒ビーズを提供することを目的とする。本発明の消毒剤は、10ppm以上のヨウ素、及び0.05w/v%以上の界面活性剤を媒体中に含む消毒剤であって、前記界面活性剤が、ノニオン系界面活性剤である。また、本発明の消毒フィルムは、ヨウ素及び界面活性剤をバインダー樹脂中に含み、前記界面活性剤が、ノニオン系界面活性剤である。さらに、本発明の消毒ビーズは、ヨウ素及び界面活性剤をバインダー樹脂中に含み、前記界面活性剤が、ノニオン系界面活性剤である。
-
-
-
-
-
-
-
-
-